271 related articles for article (PubMed ID: 18342360)
21. Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization.
White DA; Holtzman SG
J Pharmacol Exp Ther; 2005 Jul; 314(1):374-82. PubMed ID: 15843500
[TBL] [Abstract][Full Text] [Related]
22. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.
Lapham S; Forman R; Alexander M; Illeperuma A; Bohn MJ
J Subst Abuse Treat; 2009 Jan; 36(1):1-6. PubMed ID: 18775624
[TBL] [Abstract][Full Text] [Related]
23. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
Lucey MR; Silverman BL; Illeperuma A; O'Brien CP
Alcohol Clin Exp Res; 2008 Mar; 32(3):498-504. PubMed ID: 18241321
[TBL] [Abstract][Full Text] [Related]
24. An improved long-acting delivery system for narcotic antagonists.
Misra AL; Pontani RB
NIDA Res Monogr; 1981; 28():254-64. PubMed ID: 6791009
[TBL] [Abstract][Full Text] [Related]
25. Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats.
Todtenkopf MS; O'Neill KS; Kriksciukaite K; Turncliff RZ; Dean RL; Ostrovsky-Day I; Deaver DR
Addict Biol; 2009 Sep; 14(4):408-18. PubMed ID: 19489752
[TBL] [Abstract][Full Text] [Related]
26. Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats.
Richebé P; Rivalan B; Rivat C; Laulin JP; Janvier G; Maurette P; Simonnet G
Can J Anaesth; 2009 Feb; 56(2):126-35. PubMed ID: 19247760
[TBL] [Abstract][Full Text] [Related]
27. Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats.
Bartus RT; Emerich DF; Hotz J; Blaustein M; Dean RL; Perdomo B; Basile AS
Neuropsychopharmacology; 2003 Nov; 28(11):1973-82. PubMed ID: 12931140
[TBL] [Abstract][Full Text] [Related]
28. A preclinical comparison between different opioids: antinociceptive versus adverse effects.
Meert TF; Vermeirsch HA
Pharmacol Biochem Behav; 2005 Feb; 80(2):309-26. PubMed ID: 15680184
[TBL] [Abstract][Full Text] [Related]
29. Does adding low doses of oral naltrexone to morphine alter the subsequent opioid requirements and side effects in trauma patients?
Farahmand S; Ahmadi O; Dehpour A; Khashayar P
Am J Emerg Med; 2012 Jan; 30(1):75-8. PubMed ID: 21075578
[TBL] [Abstract][Full Text] [Related]
30. The peripheral antinociceptive effects of endomorphin-1 and kynurenic acid in the rat inflamed joint model.
Mecs L; Tuboly G; Nagy E; Benedek G; Horvath G
Anesth Analg; 2009 Oct; 109(4):1297-304. PubMed ID: 19762760
[TBL] [Abstract][Full Text] [Related]
31. Naltrexone effects on male sexual behavior, corticosterone, and testosterone in stressed male rats.
Retana-Márquez S; Bonilla-Jaime H; Vázquez-Palacios G; Martínez-García R
Physiol Behav; 2009 Feb; 96(2):333-42. PubMed ID: 19027764
[TBL] [Abstract][Full Text] [Related]
32. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
33. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain.
Ross EL; Hahn K
Int J Clin Pract; 2008 Mar; 62(3):471-9. PubMed ID: 18261077
[TBL] [Abstract][Full Text] [Related]
34. Discriminative stimulus effects of naltrexone after a single dose of morphine in the rat.
Easterling KW; Holtzman SG
J Pharmacol Exp Ther; 1999 Mar; 288(3):1269-77. PubMed ID: 10027868
[TBL] [Abstract][Full Text] [Related]
35. Interactions between metoclopramide and morphine: enhanced antinociception and motor dysfunction in rats.
Kamerman PR; Becker N; Fick LG
Clin Exp Pharmacol Physiol; 2007; 34(1-2):106-12. PubMed ID: 17201744
[TBL] [Abstract][Full Text] [Related]
36. Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study.
Lukas SE; Lowen SB; Lindsey KP; Conn N; Tartarini W; Rodolico J; Mallya G; Palmer C; Penetar DM
Neuroimage; 2013 Sep; 78():176-85. PubMed ID: 23571420
[TBL] [Abstract][Full Text] [Related]
37. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
Lapham SC; McMillan GP
J Addict Med; 2011 Sep; 5(3):163-9. PubMed ID: 21844831
[TBL] [Abstract][Full Text] [Related]
38. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone.
Zagon IS; Sassani JW; McLaughlin PJ
Cornea; 2006 Aug; 25(7):821-9. PubMed ID: 17068460
[TBL] [Abstract][Full Text] [Related]
39. Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats.
Ceccarelli I; De Padova AM; Fiorenzani P; Massafra C; Aloisi AM
Neuroscience; 2006 Jul; 140(3):929-37. PubMed ID: 16580783
[TBL] [Abstract][Full Text] [Related]
40. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
